 |
|
Leadership
Sharon Cload, Ph.D., Vice President, Adnexus
Ray Camphausen, Ph.D., Associate Vice President, Protein Design
Michael Gosselin, Director of Protein Sciences, DiscoveryMr. Gosselin has over 20 years of experience in the biotechnology industry, and currently oversees all discovery level protein science activities, and automation, at Adnexus. Previously, he served with increasing levels of responsibility to lead the protein sciences group to work on identification and evaluation of Adnectin™ drug candidates. Prior to Adnexus, Mr. Gosselin held positions at Praecis Pharmaceuticals, Millennium Pharmaceuticals, T-Cell Sciences and Integrated Genetics. Mr. Gosselin received a B.S. in Biology from Boston College in 1982. Samta Kundu, Senior Director, Research OperationsMs. Kundu has over 15 years business experience in the biotechnology industry. She manages legal, finance and communications functions at Adnexus, working closely with her counterparts at Bristol-Myers Squibb. At Adnexus Therapeutics, she was instrumental in organizing diligence efforts supporting partnerships, financing rounds, and the acquisition by Bristol-Myers Squibb. Prior to Adnexus, Ms. Kundu led business development for a small start-up, Consensus Pharmaceuticals; managed a patent licensing program and led or supported business discussions for Dyax, as Director of Corporate Development; and provided market analysis to launch a knee cartilage repair product as a Project Manager at Genzyme. Ms. Kundu began her career at LEK Consulting, providing strategic and financial analysis to clients in various industries, including biotech. She received her MBA from Kellogg and a B.A. from Princeton University. Kelledy Manson, Vice President, Early Candidate Assessment
Nicholas Marsh, Ph.D., Senior Director, Preclinical Discovery & DevelopmentDr. Marsh has 15 years experience in the biotech industry, and currently oversees all preclinical discovery and development activities at Adnexus. Prior to joining Adnexus, Dr. Marsh held positions of increasing responsibility at Archemix, most recently as the Director of In Vitro Pharmacology, working to develop aptamers as therapeutics. Prior to this, he worked as a Scientist at Aegera Therapeutics. Dr. Marsh completed a Post Doctoral Fellowship in David Kaplan's laboratory at McGill University, and received a Ph.D. in Pharmacology from the University of Chicago in 1995. Kathy Wilkinson, Director, Adnexus Operations
Ms. Wilkinson has over 15 years business experience in the biotechnology and high-tech industries. She currently oversees Adnexus HR, IT, facilities and lab operations groups. Prior to Adnexus, Ms. Wilkinson was the Senior Director of Human Resources at Codon Devices, Inc. where she was responsible for the development of communication strategies, talent management programs, and cultural development. Before that, Ms. Wilkinson was the Director of Human Resources for Aspect Software where she led compensation strategy and design, oversaw the HR service center, and provided business partner support to multiple functions. Prior to Aspect, she held multiple HR generalist and management roles at software companies. Ms. Wilkinson has a Bachelors degree in Sociology from Harvard University. Martin Wright, D. Phil, Associate Director, Selection TechnologiesDr. Wright joined Adnexus in 2003 as an expert in mRNA display (PROfusion) and related techniques for in vitro selection and molecular evolution. He currently oversees all Adnexus selection technologies and leads a team whose responsibilities include PROfusion, molecular biology and sequencing. He received a D. Phil from the University of Oxford under the supervision of Dr. John Sutherland and Sir Jack Baldwin. He did post-doctoral research on catalytic RNA molecules with Dr. Gerald Joyce at the Scripps Research Institute before joining Phylos as one of its first employees in 1997. He has over 14 years experience working with PROfusion on a wide range of industrial applications and over 12 years experience working with Adnectins. |
Dr. Cload has over 15 years of experience in the biotech industry, with an emphasis on affinity based drug discovery platforms. She joined Adnexus in 2008 to head Adnectin Discovery and now has overall site management responsibility. Prior to joining Adnexus, Dr. Cload spent seven years in lead discovery and technology development at Archemix Corp., most recently as Vice President, Aptamer Discovery. Previously, she developed small molecule discovery technologies for both RNA and protein targets at Anadys Pharmaceuticals. Dr. Cload holds a Ph.D. in Bio-Organic chemistry from Yale University, and was an NIH post-doctoral fellow with Peter Schultz at the University of California, Berkeley. Dr. Cload received her BA in Chemistry at New College of the University of South Florida. 
Dr. Camphausen has more than 20 years of experience in the biotech industry, with a particular focus on protein engineering and design. He has served as Associate Vice President, Protein Design since June, 2008. Prior to that, he served with increasing levels of responsibility in the discovery and research group, including, most recently, as Associate Vice President, Discovery from August 2006 to June 2008. Prior to Adnexus, he served as Vice President, Research & Discovery at Thios Pharmaceuticals, Inc., a biotechnology start-up in California. Previously, Dr. Camphausen spent 15 years at Wyeth Pharmaceuticals/Genetics Institute where he was the Associate Director and Project Leader for protein and small molecule antagonists directed toward cell adhesion molecules involved in inflammation and cardiovascular diseases. While at Wyeth Pharmaceuticals/Genetics Institute, he advanced four discovery programs to clinical development, and was also a founding member of the company's Carbohydrate Chemistry group. Dr. Camphausen has a B.A. from UC San Diego and a Ph.D. from Colorado State University. 
Ms. Manson has nearly 20 years experience in the biopharmaceutical industry. She currently oversees early manufacturing and clinical development activities related to designated Adnexus programs. Prior to this, she served as Vice President Product Development, and earlier, as head of Program Management, for Adnexus. Prior to joining Adnexus, she was a Program Executive and Sr. Director of Bioanalytical Chemistry at Therion biologics, where she was responsible for leading the development of a first- in-class novel prostate cancer vaccine from early discovery through successful proof of concept Phase 2 clinical studies. In addition, she directed the bioanalytical assessment of Therion's entire cancer vaccine portfolio which included the preparation of a BLA for a Phase 3 pancreatic cancer vaccine. Ms Manson began her biopharmaceutical career at TSI Corporation and Genzyme Transgenics where she was Director of Immunology and managed a multi-million dollar global NIH contract to evaluate novel HIV vaccine strategies. Ms Manson has a BS in Medical Technology from Michigan State University and a Masters in Biology from Worcester Polytechnical Institute.